Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EOS006215 |
Synonyms | |
Therapy Description |
Limited information is currently available on EOS006215, a putative monoclonal antibody targeting TREM2 (Mar 2025). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EOS006215 | EOS-006215|EOS 006215|EOS215|EOS 215|EOS-215 | Limited information is currently available on EOS006215, a putative monoclonal antibody targeting TREM2 (Mar 2025). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06877533 | Phase I | EOS006215 + Pembrolizumab EOS006215 | A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 As Monotherapy and in Combination with Pembrolizumab or Other Anticancer Treatments in Participants with Advanced Solid Tumors | Not yet recruiting | USA | BEL | 0 |